Overview

Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
In ASCOT study, lipid lowering with a statin provided additional beneficial effects in hypertensive patients with average levels of serum total cholesterol. However, the underlying mechanism of statins to improve clinical outcomes in hypertension is unclear and the effect of statins on coronary flow reserve (CFR) has not been examined in hypertensive patients. Therefore, it is clinically important and timely project to measure CFR non-invasively using echocardiography and to elucidate the mechanism of clinical benefits of statins in hypertensive patients with cardiovascular risk. The investigators try to evaluate the effect of rosuvastatin on CFR by measuring the change of CFR after 1 year treatment of rosuvastatin, and to correlate CFR with LDL-cholesterol and CRP.
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
AstraZeneca
Treatments:
Rosuvastatin Calcium